Aptevo Therapeutics revenue APVO

Sales by quarter and over the last twelve months, from 2015.

Aptevo Therapeutics' revenue was $3.1M over the twelve months to Dec 31, 2022, down 75% on a year earlier.

In its latest quarter, Q4 FY22, it was $0, down 100% on the same quarter a year before.

Over the five fiscal years to FY2022 it shrank 27% a year on average.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q4 FY22	Dec 31, 2022	$0	−100%	$3.1M
Q3 FY22	Sep 30, 2022	$0	−100%	$6.8M
Q2 FY22	Jun 30, 2022	$0	−100%	$9.9M
Q1 FY22	Mar 31, 2022	$3.1M	+29%	$13M
Q4 FY21	Dec 31, 2021	$3.7M	+54%	$12.3M
Q3 FY21	Sep 30, 2021	$3.1M	+112%	$11M
Q2 FY21	Jun 30, 2021	$3.1M	+558%	$9.4M
Q1 FY21	Mar 31, 2021	$2.4M	n/a	$6.7M
Q4 FY20	Dec 31, 2020	$2.4M	−74%	n/a
Q3 FY20	Sep 30, 2020	$1.5M	−84%	n/a
Q2 FY20	Jun 30, 2020	$473K	−94%	n/a
Q4 FY19	Dec 31, 2019	$9M	+42%	$32.4M

Companies in Healthcare nearest Aptevo Therapeutics' size, closest first, today.

Company	Revenue, 12 months	Growth
APVOAptevo Therapeutics	n/m
OXBROXBRIDGE RE HOLDINGS	$2.8M	+40% a year
EDUCEducational Development	$20M	−32% a year
GTIMGood Times Restaurants	$135.1M	−6% a year
MDRRMedalist Diversified	$9.6M	−1% a year
BCGBinah Capital	$191.9M	+8% a year
VIPVulcan Infrastructure & Power	$50.9M	−14% a year
MXCMexco Energy	$6.7M	−9% a year
CKXCKX Lands	$693.4K	−17% a year
MSGMMotorsport Games	$14.5M	+79% a year
ATCHAtlasClear	$20.1M	+85% a year
Peer median	$17.3M